



Innovative Medicines Initiative

# EFPIA Perspectives

Richard Bergström  
Director General



efpia


---

Open Information Day – 17 June 2011 - Brussels


# The challenge



## R&D EXPENDITURE – OUTPUT RETURN ON INVESTMENT 1970-2007



1 Includes NCEs and BLAs. BLAs included 1996 onward; biologics approvals in prior years assumed negligible



The **European Union and the pharmaceutical industry** have joined forces to make **drug R&D processes in Europe more efficient and effective** and enhance Europe's **competitiveness in the sector.**

# Vision



Make **drug R&D processes in Europe** more efficient and effective  
and  
enhance Europe's **competitiveness in the sector**



Idea generation

Basic research  
and non-clinical  
testing

Human testing

Regulatory  
approval  
and Health  
Technology  
assessment

Marketed  
drug

To the benefit of EU: Improved healthcare status of individuals and society, and positive economical impact  
To the benefit of Pharma Industry: facilitate development of next generation drugs

# Overview Call 4



## Cluster 1: EU Medical Information System

1. Building up a European Medical Information Framework to improve healthcare and facilitate research
2. ETIKS: European Translational Research Infrastructure & Knowledge Management Services

## Cluster 2: Chemistry, Manufacturing and Control

3. Delivery and Targeting Mechanisms for Biological Macromolecules
4. In vivo predictive biopharmaceutics tools for oral drug delivery
5. Sustainable Chemistry – Delivering Medicines for the 21st Century

## Cluster 3: Technology and Molecular Disease Understanding

6. Human Induced Pluripotent Stem (hiPS) Cells for Drug Discovery and Safety Assessment
7. Understanding and Optimising Binding Kinetics in Drug Discovery